DE3477732D1 - Method for producing microcapsule - Google Patents

Method for producing microcapsule

Info

Publication number
DE3477732D1
DE3477732D1 DE8484307570T DE3477732T DE3477732D1 DE 3477732 D1 DE3477732 D1 DE 3477732D1 DE 8484307570 T DE8484307570 T DE 8484307570T DE 3477732 T DE3477732 T DE 3477732T DE 3477732 D1 DE3477732 D1 DE 3477732D1
Authority
DE
Germany
Prior art keywords
producing microcapsule
microcapsule
producing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE8484307570T
Other languages
English (en)
Inventor
Hiroaki Okada
Yasuaki Ogawa
Takatsuka Yashiki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16545089&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3477732(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of DE3477732D1 publication Critical patent/DE3477732D1/de
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B01J13/06—Making microcapsules or microballoons by phase separation
    • B01J13/12—Making microcapsules or microballoons by phase separation removing solvent from the wall-forming material solution
    • B01J13/125—Making microcapsules or microballoons by phase separation removing solvent from the wall-forming material solution by evaporation of the solvent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/15—Suppositories
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]
    • Y10T428/2985—Solid-walled microcapsule from synthetic polymer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2989—Microcapsule with solid core [includes liposome]
DE8484307570T 1983-11-04 1984-11-02 Method for producing microcapsule Expired DE3477732D1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP58207760A JPS60100516A (ja) 1983-11-04 1983-11-04 徐放型マイクロカプセルの製造法

Publications (1)

Publication Number Publication Date
DE3477732D1 true DE3477732D1 (en) 1989-05-24

Family

ID=16545089

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8484307570T Expired DE3477732D1 (en) 1983-11-04 1984-11-02 Method for producing microcapsule

Country Status (13)

Country Link
US (7) US4652441A (de)
EP (1) EP0145240B1 (de)
JP (1) JPS60100516A (de)
BG (1) BG60493B2 (de)
CA (1) CA1233414A (de)
DE (1) DE3477732D1 (de)
ES (1) ES8605983A1 (de)
GR (1) GR80818B (de)
HK (1) HK3792A (de)
HU (1) HU193910B (de)
IE (1) IE57721B1 (de)
PT (1) PT79450B (de)
SG (1) SG103491G (de)

Families Citing this family (543)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8514090D0 (en) * 1985-06-04 1985-07-10 Sandoz Ltd Organic compounds
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
ATE61935T1 (de) * 1985-02-07 1991-04-15 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
JP2551756B2 (ja) * 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
US4734399A (en) * 1985-08-06 1988-03-29 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
US5112619A (en) * 1985-11-12 1992-05-12 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulation
ES2039203T3 (es) * 1985-11-22 1993-09-16 Takeda Chemical Industries, Ltd. Composicion de liposomas.
CA1275922C (en) * 1985-11-28 1990-11-06 Harunobu Amagase Treatment of cancer
US4780320A (en) * 1986-04-29 1988-10-25 Pharmetrix Corp. Controlled release drug delivery system for the periodontal pocket
US4832686A (en) * 1986-06-24 1989-05-23 Anderson Mark E Method for administering interleukin-2
JPS6341416A (ja) * 1986-08-08 1988-02-22 Takeda Chem Ind Ltd 鎮痛性ペプチド含有マイクロカプセルの製造法
JP2526589B2 (ja) * 1986-08-08 1996-08-21 武田薬品工業株式会社 ペプチド含有マイクロカプセルおよびその製造法
JPH0725689B2 (ja) * 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
CA1321048C (en) * 1987-03-05 1993-08-10 Robert W. J. Lencki Microspheres and method of producing same
US4857335A (en) * 1987-03-27 1989-08-15 Lim Technology Laboratories, Inc. Liquid controlled release formulations and method of producing same via multiple emulsion process
US5143661A (en) * 1987-05-26 1992-09-01 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules
US5500228A (en) * 1987-05-26 1996-03-19 American Cyanamid Company Phase separation-microencapsulated pharmaceuticals compositions useful for alleviating dental disease
US4880632A (en) * 1987-09-08 1989-11-14 The United States Of America Prevention of fescue toxicosis
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
JPH0725649B2 (ja) * 1987-10-12 1995-03-22 而至歯科工業株式会社 消毒剤含有アルギン酸印象材
US5187150A (en) * 1987-10-14 1993-02-16 Debiopharm S.A. Polyester-based composition for the controlled release of polypeptide medicinal substances
WO1989003678A1 (en) * 1987-10-30 1989-05-05 Stolle Research & Development Corporation Low residual solvent microspheres and microencapsulation process
US5051261A (en) * 1987-11-24 1991-09-24 Fmc Corporation Method for preparing a solid sustained release form of a functionally active composition
US5290562A (en) * 1987-11-27 1994-03-01 L V M H Recherche Compositions and methods employing liposomes including tyrosine or a tyrosine derivative
ES2058351T3 (es) * 1988-01-29 1994-11-01 Sumitomo Pharma Un procedimiento para producir una formulacion de liberacion sostenida que es adecuada para el uso humano y veterinario.
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US4952408A (en) * 1988-05-23 1990-08-28 Georgetown University Liposome-encapsulated vinca alkaloids and their use in combatting tumors
US5271945A (en) * 1988-07-05 1993-12-21 Takeda Chemical Industries, Ltd. Sustained release microcapsule for water soluble drug
US5298255A (en) * 1988-10-28 1994-03-29 Terumo Kabushiki Kaisha Antithrombic medical material, artificial internal organ, and method for production of antithrombic medical material
ATE105177T1 (de) * 1988-12-22 1994-05-15 American Cyanamid Co Verfahren zur behandlung von periodontitis durch protrahierte wirkstoffabgabe von arzneimitteln in der zahnhoehle, zusammensetzung davon und vorrichtung zur verabreichung.
US5236355A (en) * 1988-12-22 1993-08-17 American Cyanamid Company Apparatus for the treatment of periodontal disease
US5051305A (en) * 1988-12-30 1991-09-24 Arcade, Inc. Stabilized perfume-containing microcapsules and method of preparing the same
EP0471036B2 (de) * 1989-05-04 2004-06-23 Southern Research Institute Einkapselungsverfahren
IT8920486A0 (it) * 1989-05-12 1989-05-12 Isf Spa Composizioni farmaceutiche.
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
JP2571874B2 (ja) * 1989-11-06 1997-01-16 アルカーメス コントロールド セラピューティクス，インコーポレイテッド タンパク質マイクロスフェア組成物
FR2654337B1 (fr) * 1989-11-15 1994-08-05 Roussel Uclaf Nouvelles microspheres injectables biodegradables procede de preparation et suspensions injectables les renfermant.
US5198220A (en) * 1989-11-17 1993-03-30 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
JP2958103B2 (ja) * 1989-12-12 1999-10-06 エーザイ株式会社 プラズマ照射固形製剤
MY107937A (en) * 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
JP2653255B2 (ja) 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
US5478564A (en) * 1990-02-22 1995-12-26 Teva Pharmaceutical Industries, Ltd. Preparation of microparticles for controlled release of water-soluble substances
DE69129770T2 (de) * 1990-04-13 1998-11-19 Takeda Chemical Industries Ltd Biologisch abbaubare hochmolekulare Polymere, ihre Herstellung und ihre Verwendung
US6517859B1 (en) 1990-05-16 2003-02-11 Southern Research Institute Microcapsules for administration of neuroactive agents
DE69133136T2 (de) * 1990-05-16 2003-06-18 Southern Res Inst Birmingham Mikrokapseln mit gesteuerter freigabe sowie deren verwendung zur stimulierung des nervenfaserwachstums
JP3116311B2 (ja) * 1990-06-13 2000-12-11 エーザイ株式会社 マイクロスフィアの製法
US5364839A (en) * 1990-06-18 1994-11-15 Genetics Institute, Inc. Osteoinductive pharmaceutical formulations
GB9016885D0 (en) * 1990-08-01 1990-09-12 Scras Sustained release pharmaceutical compositions
US5418010A (en) * 1990-10-05 1995-05-23 Griffith Laboratories Worldwide, Inc. Microencapsulation process
KR930006431B1 (ko) * 1990-10-11 1993-07-16 재단법인 한국화학연구소 약물의 미세캡슐화 방법
NZ240214A (en) * 1990-10-16 1993-02-25 Takeda Chemical Industries Ltd Polymer compositions comprising a polylactic acid and a copolymer of glycolic acid and a hydroxycarboxylic acid; use as carrier for prolonged release pharmaceutical compositions of water soluble drugs
US5206023A (en) * 1991-01-31 1993-04-27 Robert F. Shaw Method and compositions for the treatment and repair of defects or lesions in cartilage
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5654009A (en) * 1991-03-25 1997-08-05 Fujisawa Pharmaceutical Co., Ltd. Delayed action preparation
JPH04364131A (ja) * 1991-04-03 1992-12-16 Sanwa Kagaku Kenkyusho Co Ltd 易吸収性モチリン製剤
KR0145278B1 (ko) * 1991-06-21 1998-07-15 브루스 엠. 에이센 골형성원 단백질 약제
US5252337A (en) * 1991-06-25 1993-10-12 Eurand America, Inc. Controlled release calcium channel blocker microcapsules
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
US5270300A (en) * 1991-09-06 1993-12-14 Robert Francis Shaw Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone
KR100259989B1 (ko) * 1991-10-01 2000-08-01 모리다 가쓰라 서방성 마이크로캡슐 제제 및 그의 제조법
US5288502A (en) * 1991-10-16 1994-02-22 The University Of Texas System Preparation and uses of multi-phase microspheres
US5837747A (en) * 1991-10-29 1998-11-17 Vivorx, Inc. Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
DK0617612T3 (da) * 1991-12-18 1998-04-14 Warner Lambert Co Fremgangsmåde til fremstilling af en fast dispersion
WO1993015722A1 (en) * 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
JP3004724B2 (ja) * 1992-04-06 2000-01-31 ユーロプラスティ インコーポレイテッド ミクロ粒子注入による逆流障害の処置
US5922652A (en) * 1992-05-05 1999-07-13 Procter & Gamble Microencapsulated oil field chemicals
US20030035845A1 (en) * 1992-06-11 2003-02-20 Zale Stephen E. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) * 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
JP2651320B2 (ja) * 1992-07-16 1997-09-10 田辺製薬株式会社 徐放性マイクロスフェア製剤の製造方法
AU4198793A (en) † 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
DK0582459T3 (da) * 1992-08-07 1998-04-27 Takeda Chemical Industries Ltd Fremstilling af mikrokapsler af vandopløselige lægemidler
JP3277342B2 (ja) * 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
US5922340A (en) 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
DE69331387T2 (de) * 1992-09-10 2002-08-22 Childrens Medical Center Biodegradierbare polymeren matrizen mit verzoegerter freisetzung von lokalanaesthetika
US5700485A (en) 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
DE4231493A1 (de) * 1992-09-21 1994-03-24 Nordmark Arzneimittel Gmbh Verfahren zur Herstellung von Pellets aus einem Ephedrinderivat
EP0595030A3 (de) * 1992-10-01 1995-06-07 Tanabe Seiyaku Co Mehrkern-Mikrosphären mit verzögerter Wirkstoffabgabe und Verfahren zu deren Herstellung.
US5242910A (en) * 1992-10-13 1993-09-07 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
US5310742A (en) * 1992-11-30 1994-05-10 Elias Alan N Uses for thioureylenes
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
JPH06239746A (ja) * 1993-02-12 1994-08-30 Mayumi Okada モルヒネ徐放性製剤
ES2153418T3 (es) * 1993-02-23 2001-03-01 Genentech Inc Estabilizacion de polipeptidos tratados con solventes organicos por medio de excipientes.
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
ES2070076B1 (es) * 1993-04-20 1996-04-16 Cusi Lab Metodo para aumentar la estabilidad de las nanocapsulas durante su almacenamiento.
US5447725A (en) * 1993-06-11 1995-09-05 The Procter & Gamble Company Methods for aiding periodontal tissue regeneration
US5449663A (en) * 1993-06-11 1995-09-12 Bicher; Haim I. Antineoplastic compositions
US6913767B1 (en) 1993-10-25 2005-07-05 Genentech, Inc. Compositions for microencapsulation of antigens for use as vaccines
US6080429A (en) * 1993-10-25 2000-06-27 Genentech, Inc. Method for drying microspheres
US5643605A (en) * 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
AU693821B2 (en) * 1993-11-18 1998-07-09 Sirtex Medical Limited Controlled release preparation
US5474985A (en) * 1993-12-22 1995-12-12 The Regents Of The University Of California Preventing and treating elevated intraocular pressure associated with administered or endogenous steroids using non-steroidal cyclooxygenase inhibitors
ATE178789T1 (de) * 1994-02-21 1999-04-15 Takeda Chemical Industries Ltd Polyester matrix für eine pharmazeutische zusammensetzung mit verzögerter freigabe
IE940292A1 (en) * 1994-04-06 1995-10-18 Elan Corp Plc Biodegradable microcapsules and method for their manufacture
US5538733A (en) * 1994-07-07 1996-07-23 Willmar Poultry Company, Inc. Method of priming an immune response in a one-day old animal
CA2150060C (en) * 1994-07-08 2000-01-11 John T. Biggs Seamless multimedia conferencing system using enhanced endpoint devices
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5520923A (en) * 1994-09-19 1996-05-28 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
DE4443175A1 (de) * 1994-12-05 1996-06-13 Jenapharm Gmbh Neue pulsatile Arzneiform
US5599535A (en) * 1995-06-07 1997-02-04 Regents Of The University Of California Methods for the cyto-protection of the trabecular meshwork
US5879712A (en) * 1995-06-07 1999-03-09 Sri International Method for producing drug-loaded microparticles and an ICAM-1 dosage form so produced
US5674888A (en) * 1995-06-07 1997-10-07 University Of California Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
MX9700850A (es) 1995-06-09 1997-09-30 Euro Celtique Sa Formulaciones y metodos para proporcionar anestesia local prolongada.
US5916597A (en) * 1995-08-31 1999-06-29 Alkermes Controlled Therapeutics, Inc. Composition and method using solid-phase particles for sustained in vivo release of a biologically active agent
TW448055B (en) * 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
US5702717A (en) * 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
US5665428A (en) * 1995-10-25 1997-09-09 Macromed, Inc. Preparation of peptide containing biodegradable microspheres by melt process
EP0862419B2 (de) 1995-11-09 2010-11-17 Microbiological Research Authority Mikroverkapselte dna zur impfung und gentherapie
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
CA2192773C (en) 1995-12-15 2008-09-23 Hiroaki Okada Production of sustained-release preparation for injection
US5747060A (en) * 1996-03-26 1998-05-05 Euro-Celtique, S.A. Prolonged local anesthesia with colchicine
JPH11511763A (ja) 1996-06-24 1999-10-12 ユーロ―セルティーク，エス．エイ． 安全な局所麻酔の提供方法
US8303981B2 (en) 1996-08-27 2012-11-06 Baxter International Inc. Fragmented polymeric compositions and methods for their use
US6066325A (en) 1996-08-27 2000-05-23 Fusion Medical Technologies, Inc. Fragmented polymeric compositions and methods for their use
US7435425B2 (en) 2001-07-17 2008-10-14 Baxter International, Inc. Dry hemostatic compositions and methods for their preparation
US7871637B2 (en) 1996-08-27 2011-01-18 Baxter International Inc. Dry hemostatic compositions and methods for their preparation
US8603511B2 (en) 1996-08-27 2013-12-10 Baxter International, Inc. Fragmented polymeric compositions and methods for their use
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
US6046187A (en) * 1996-09-16 2000-04-04 Children's Medical Center Corporation Formulations and methods for providing prolonged local anesthesia
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
US20020182258A1 (en) * 1997-01-22 2002-12-05 Zycos Inc., A Delaware Corporation Microparticles for delivery of nucleic acid
US5945126A (en) * 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
US7150881B2 (en) 1997-06-26 2006-12-19 Mylan Technologies, Inc. Adhesive mixture for transdermal delivery of highly plasticizing drugs
AU751267B2 (en) 1997-06-30 2002-08-08 Monsanto Technology Llc Microparticles containing agricultural active ingredients
IL129951A0 (en) * 1997-07-02 2000-02-29 Euro Celtique Sa Prolonged anesthesia in joints and body spaces
US6391452B1 (en) * 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
US5902598A (en) * 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
EP1014946B1 (de) 1997-09-18 2010-04-07 Pacira Pharmaceuticals, Inc. Retardierte freisetzung liposmaler anesthetischer zusammensetzungen.
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6117949A (en) * 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6004573A (en) * 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6045835A (en) * 1997-10-08 2000-04-04 Givaudan Roure (International) Sa Method of encapsulating flavors and fragrances by controlled water transport into microcapsules
US6106875A (en) * 1997-10-08 2000-08-22 Givaudan Roure (International) Sa Method of encapsulating flavors and fragrances by controlled water transport into microcapsules
SE512663C2 (sv) * 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
TW577758B (en) * 1997-10-27 2004-03-01 Ssp Co Ltd Intra-articular preparation for the treatment of arthropathy
JP4234803B2 (ja) * 1997-10-27 2009-03-04 久光製薬株式会社 薬物放出速度が制御された医薬組成物
EP1030652B1 (de) * 1997-11-14 2012-04-25 Pacira Pharmaceuticals, Inc. Herstellung von multivesikulären liposomen
EP1049458B1 (de) 1998-01-21 2003-03-26 Takeda Chemical Industries, Ltd. Verfahren zur gerfriertrocknung von präparaten mit verzörgerter wirkstoffabgabe
US20030180368A1 (en) * 1998-03-14 2003-09-25 Cenes Drug Delivery Limited Production of microparticles
CN1203846C (zh) 1998-03-19 2005-06-01 布里斯托尔-迈尔斯斯奎布公司 高溶解性药物的双相控释递送系统和方法
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US7128927B1 (en) * 1998-04-14 2006-10-31 Qlt Usa, Inc. Emulsions for in-situ delivery systems
SE9801288D0 (sv) 1998-04-14 1998-04-14 Astra Ab Vaccine delivery system and metod of production
US6217844B1 (en) * 1998-04-27 2001-04-17 Praecis Pharmaceuticals, Inc. Methods for detecting lesions in dense breast tissue using LHRH antagonists
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
US6451335B1 (en) 1998-07-02 2002-09-17 Euro-Celtique S.A. Formulations and methods for providing prolonged local anesthesia
AU752225B2 (en) 1998-07-17 2002-09-12 Pacira Pharmaceuticals, Inc. Biodegradable compositions for the controlled release of encapsulated substances
US20070009605A1 (en) * 1998-07-23 2007-01-11 Ignatious Francis X Encapsulation of water soluble peptides
US6200590B1 (en) 1998-08-10 2001-03-13 Naphcare, Inc. Controlled, phased-release suppository and its method of production
US7662409B2 (en) * 1998-09-25 2010-02-16 Gel-Del Technologies, Inc. Protein matrix materials, devices and methods of making and using thereof
US20050147690A1 (en) * 1998-09-25 2005-07-07 Masters David B. Biocompatible protein particles, particle devices and methods thereof
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6270802B1 (en) 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
US6204308B1 (en) 1999-03-01 2001-03-20 Novartis Ag Organic compounds
US6217895B1 (en) * 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US20040121014A1 (en) * 1999-03-22 2004-06-24 Control Delivery Systems, Inc. Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6287588B1 (en) * 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
US6709427B1 (en) * 1999-08-05 2004-03-23 Kensey Nash Corporation Systems and methods for delivering agents into targeted tissue of a living being
WO2001010416A1 (en) * 1999-08-11 2001-02-15 Alkermes Controlled Therapeutics, Inc. Method of delivering a chemotherapeutic agent to a solid tumor
US6495155B1 (en) * 1999-08-27 2002-12-17 Southern Research Institute Injectable opioid partial agonist or opioid antagonist microparticle compositions and their use in reducing consumption of abused substances
US7651703B2 (en) * 1999-10-15 2010-01-26 Genentech, Inc. Injection vehicle for polymer-based formulations
EP2286847A1 (de) 1999-10-15 2011-02-23 Genetics Institute, LLC Hyaluronsäure enthaltende Zusammensetzungen zur Abgabe osteogener Proteine
US7582311B1 (en) 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
US6682754B2 (en) 1999-11-24 2004-01-27 Willmar Poultry Company, Inc. Ovo delivery of an immunogen containing implant
US7771746B2 (en) * 1999-12-03 2010-08-10 Polichem Sa Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof
ES2169980B1 (es) 1999-12-17 2003-11-01 Lipotec Sa Microcapsulas para la liberacion prolongada de farmacos.
US6656467B2 (en) * 2000-01-27 2003-12-02 Medimmune, Inc. Ultra high affinity neutralizing antibodies
TWI284048B (en) 2000-01-27 2007-07-21 Zentaris Ag Compressed microparticles for dry injection
US6465425B1 (en) * 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
DK1259547T3 (da) 2000-03-01 2012-10-15 Medimmune Inc Højpotente, rekombinante antistoffer og fremgangsmåde til fremstilling heraf
US7153525B1 (en) * 2000-03-22 2006-12-26 The University Of Kentucky Research Foundation Microemulsions as precursors to solid nanoparticles
US20030124177A1 (en) * 2000-04-26 2003-07-03 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
US7179483B2 (en) * 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
WO2001080796A1 (en) * 2000-04-26 2001-11-01 Watson Pharmaceuticals, Inc. Minimizing adverse experience associated with oxybutynin therapy
US7029694B2 (en) * 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US6589549B2 (en) * 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
US7018645B1 (en) 2000-04-27 2006-03-28 Macromed, Inc. Mixtures of various triblock polyester polyethylene glycol copolymers having improved gel properties
AR023940A1 (es) 2000-05-03 2002-09-04 Eriochem Sa Procedimiento para la produccion de microcapsulas de liberacion prolongada de peptidos solubles en agua
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
CN1141974C (zh) * 2000-06-07 2004-03-17 张昊 结肠定位释放的口服生物制剂
EP1297850B1 (de) 2000-07-05 2015-08-19 Takeda Pharmaceutical Company Limited Medizinische zusammensetzungen zur behandlung von mit sexualhormonen verbundenen erkrankungen
JP5046447B2 (ja) * 2000-08-07 2012-10-10 和光純薬工業株式会社 乳酸重合体及びその製造方法
WO2003079972A2 (en) 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
FR2814380B1 (fr) * 2000-09-25 2002-11-08 Serobiologiques Lab Sa Poudre de microcapsules et procede d'obtention
EP1335661B1 (de) 2000-10-27 2009-05-06 Baxter Healthcare S.A. Herstellung von mikrokügelchen
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
DE60128261T3 (de) 2000-12-21 2016-06-30 Alrise Biosystems Gmbh Verfahren umfassend einen induzierten phasenübergang zur herstellung von hydrophobe wirkstoffe enthaltenden mikropartikeln
WO2002058670A1 (en) * 2001-01-25 2002-08-01 Euroceltique S.A. Local anesthetic, and method of use
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US6777000B2 (en) * 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
FR2822834B1 (fr) * 2001-04-02 2005-02-25 Flamel Tech Sa Suspension colloidale de nanoparticules a base de copolymeres amphiphile pour la vectorisation de principes actifs et leur mode de preparation
MXPA03010679A (es) 2001-05-23 2004-03-02 Tanabe Seiyaku Co Una composicion para acelerar la cicatrizacion de fractura osea.
ES2427930T3 (es) 2001-05-23 2013-11-04 Mitsubishi Tanabe Pharma Corporation Composición terapéutica para el tratamiento regenerativo de enfermedades de los cartílagos
IL158819A0 (en) * 2001-05-31 2004-05-12 Skyepharma Inc Encapsulation of nanosuspensions in liposomes and microspheres
JP2004535431A (ja) 2001-06-22 2004-11-25 サザン バイオシステムズ， インコーポレイテッド ゼロ次長期放出同軸インプラント
TWI332407B (en) 2001-06-29 2010-11-01 Takeda Chemical Industries Ltd Controlled release composition and method of producting the same
TWI225416B (en) 2001-06-29 2004-12-21 Takeda Chemical Industries Ltd Sustained-release composition and process for producing the same
WO2003004032A1 (en) 2001-07-06 2003-01-16 Endo Pharmaceuticals, Inc. Oral administration of 6-hydroxy-oxymorphone for use as an analgesic
ES2292775T3 (es) * 2001-07-06 2008-03-16 Penwest Pharmaceuticals Co. Formulaciones de liberacion prolongada de oximorfona.
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
US7615233B2 (en) 2001-07-10 2009-11-10 Canon Kabushiki Kaisha Particulate construct comprising polyhydroxyalkanoate and method for producing it
DK1418890T3 (da) * 2001-08-16 2008-08-11 Baxter Int Drivmiddel-baserede mikropartikelformuleringer
US20080026068A1 (en) * 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
ATE381963T1 (de) * 2001-10-26 2008-01-15 Octoplus Technologies B V Verfahren zur herstellung von gereinigten partikeln
CA2466659A1 (en) 2001-11-13 2003-05-22 Takeda Chemical Industries, Ltd. Anticancer agents
US7829109B2 (en) 2001-11-14 2010-11-09 Durect Corporation Catheter injectable depot compositions and uses thereof
MXPA04004664A (es) * 2001-11-14 2004-09-10 Alza Corp Composiciones de deposito inyectables.
US7620451B2 (en) 2005-12-29 2009-11-17 Ardian, Inc. Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach
US9636174B2 (en) 2002-04-08 2017-05-02 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation
US8774913B2 (en) 2002-04-08 2014-07-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for intravasculary-induced neuromodulation
US20140018880A1 (en) 2002-04-08 2014-01-16 Medtronic Ardian Luxembourg S.A.R.L. Methods for monopolar renal neuromodulation
US9308043B2 (en) 2002-04-08 2016-04-12 Medtronic Ardian Luxembourg S.A.R.L. Methods for monopolar renal neuromodulation
US7162303B2 (en) 2002-04-08 2007-01-09 Ardian, Inc. Renal nerve stimulation method and apparatus for treatment of patients
US6978174B2 (en) * 2002-04-08 2005-12-20 Ardian, Inc. Methods and devices for renal nerve blocking
US7756583B2 (en) 2002-04-08 2010-07-13 Ardian, Inc. Methods and apparatus for intravascularly-induced neuromodulation
US8150519B2 (en) 2002-04-08 2012-04-03 Ardian, Inc. Methods and apparatus for bilateral renal neuromodulation
US8774922B2 (en) 2002-04-08 2014-07-08 Medtronic Ardian Luxembourg S.A.R.L. Catheter apparatuses having expandable balloons for renal neuromodulation and associated systems and methods
US8131371B2 (en) 2002-04-08 2012-03-06 Ardian, Inc. Methods and apparatus for monopolar renal neuromodulation
US8145317B2 (en) 2002-04-08 2012-03-27 Ardian, Inc. Methods for renal neuromodulation
US9308044B2 (en) 2002-04-08 2016-04-12 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation
US8145316B2 (en) 2002-04-08 2012-03-27 Ardian, Inc. Methods and apparatus for renal neuromodulation
US20080213331A1 (en) 2002-04-08 2008-09-04 Ardian, Inc. Methods and devices for renal nerve blocking
US7617005B2 (en) 2002-04-08 2009-11-10 Ardian, Inc. Methods and apparatus for thermally-induced renal neuromodulation
US7653438B2 (en) 2002-04-08 2010-01-26 Ardian, Inc. Methods and apparatus for renal neuromodulation
US20070129761A1 (en) 2002-04-08 2007-06-07 Ardian, Inc. Methods for treating heart arrhythmia
US20070135875A1 (en) 2002-04-08 2007-06-14 Ardian, Inc. Methods and apparatus for thermally-induced renal neuromodulation
US7853333B2 (en) 2002-04-08 2010-12-14 Ardian, Inc. Methods and apparatus for multi-vessel renal neuromodulation
US8175711B2 (en) 2002-04-08 2012-05-08 Ardian, Inc. Methods for treating a condition or disease associated with cardio-renal function
US8347891B2 (en) 2002-04-08 2013-01-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen
CN100553625C (zh) 2002-04-09 2009-10-28 弗拉梅技术公司 活性成分微囊的口服混悬液
AU2003225212A1 (en) * 2002-04-29 2003-11-17 Gel-Del Technologies, Inc. Biomatrix structural containment and fixation systems and methods of use thereof
US8871241B2 (en) * 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
FR2840614B1 (fr) * 2002-06-07 2004-08-27 Flamel Tech Sa Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
US20030228366A1 (en) * 2002-06-11 2003-12-11 Chung Shih Reconstitutable compositions of biodegradable block copolymers
US7649023B2 (en) * 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
US7166133B2 (en) * 2002-06-13 2007-01-23 Kensey Nash Corporation Devices and methods for treating defects in the tissue of a living being
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
AU2003244157A1 (en) 2002-06-25 2004-01-06 Takeda Pharmaceutical Company Limited Process for producing sustained-release composition
US7160551B2 (en) * 2002-07-09 2007-01-09 The Board Of Trustees Of The University Of Illinois Injectable system for controlled drug delivery
FR2843117B1 (fr) * 2002-07-30 2004-10-15 Flamel Tech Sa Polyaminoacides fonctionnalises par au moins un groupement hydrophobe et leurs applications notamment therapeutiques
MXPA05001244A (es) 2002-07-31 2005-06-08 Alza Corp Composiciones de deposito de polimero multimodal inyectable y usos de las mismas.
WO2004012703A1 (en) 2002-07-31 2004-02-12 Alza Corporation Injectable depot compositions and uses thereof
WO2004012715A1 (en) * 2002-08-02 2004-02-12 Penwest Pharmaceuticals Company Sustained release formulations of metformin
EP2277551B1 (de) 2002-09-06 2013-05-08 Cerulean Pharma Inc. Polymere auf basis von cyclodextrin zur verabreichung von an diese kovalent gebundene arzneimittel
US20060189554A1 (en) * 2002-09-24 2006-08-24 Russell Mumper Nanoparticle-Based vaccine delivery system containing adjuvant
US20040086566A1 (en) * 2002-11-04 2004-05-06 Alpharma, Inc. Waxy matrix dosage forms
KR100709015B1 (ko) * 2002-11-13 2007-04-18 (주)아모레퍼시픽 지속적 약물방출이 가능한 고분자 미립구 및 그 제조방법
JP2006508967A (ja) * 2002-11-14 2006-03-16 シャー／カーシュマン ラボラトリーズ インコーポレイテッド 改善された持続放出性を有する経口テストステロン供与システム
WO2004060968A1 (fr) * 2002-12-04 2004-07-22 Flamel Technologies Polyaminoacides fonctionnalises par au moins un groupement (oligo)aminoacide et leurs applications notamment therapeutiques
EP3597262B1 (de) 2002-12-20 2023-12-27 Xeris Pharmaceuticals, Inc. Formulierung für intrakutane injektion
US20070218139A1 (en) * 2002-12-20 2007-09-20 Smith Thomas J High Pressure Compaction For Pharmaceutical Formulations
CA2553699A1 (en) * 2003-02-11 2005-08-26 Venture Management Alliance, Llc Material incapsulation system
EP1622540A4 (de) * 2003-03-11 2009-12-30 Qlt Usa Inc Formulierungen für zellen-plan-abhängige krebsmittel
US9445901B2 (en) * 2003-03-12 2016-09-20 Deger C. Tunc Prosthesis with sustained release analgesic
KR20050115315A (ko) * 2003-03-26 2005-12-07 가부시키가이샤 엘티티 바이오파마 약물 전달 및 서방성 약물 방출을 표적으로 하는 정맥 내 나노입자
ES2665464T3 (es) * 2003-03-28 2018-04-25 Sigmoid Pharma Limited Forma de dosificación oral sólida que contiene microcápsulas sin costuras
JP2004331750A (ja) 2003-05-02 2004-11-25 Canon Inc ポリヒドロキシアルカノエートを含有する磁性構造体及びその製造方法ならびにその用途
FR2855521B1 (fr) * 2003-05-28 2005-08-05 Flamel Tech Sa Polyaminoacides fonctionnalises par au moins un groupement h ydrophobe et leurs applications notamment therapeutiques.
US8834864B2 (en) 2003-06-05 2014-09-16 Baxter International Inc. Methods for repairing and regenerating human dura mater
US8465537B2 (en) * 2003-06-17 2013-06-18 Gel-Del Technologies, Inc. Encapsulated or coated stent systems
EP1660039B1 (de) 2003-07-18 2016-09-28 Oakwood Laboratories L.L.C. Prävention von molekulargewichtreduktion des polymers, bildung von unreinheiten und gelierung in polymer-zusammensetzungen
US20070092452A1 (en) * 2003-07-18 2007-04-26 Julia Rashba-Step Methods for fabrication, uses, compositions of inhalable spherical particles
SG135204A1 (en) * 2003-07-18 2007-09-28 Baxter Int Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
WO2005009375A2 (en) * 2003-07-22 2005-02-03 Baxter International Inc. Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof
US20090214644A1 (en) * 2003-07-31 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations with reduced adverse effects
US20050025825A1 (en) 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
US7927626B2 (en) * 2003-08-07 2011-04-19 Ethicon, Inc. Process of making flowable hemostatic compositions and devices containing such compositions
RS20060132A (en) 2003-08-08 2008-06-05 Biovail Laboratories International Srl., Modified-release tablet of bupropion hydrochloride
EP1660013A4 (de) 2003-08-26 2011-07-20 Gel Del Technologies Inc Protein-biomaterialien und biokoazervate und herstellungs- und verwendungsverfahren dafür
FR2860516B1 (fr) * 2003-10-03 2006-01-13 Flamel Tech Sa Homopolyaminoacides telecheliques fonctionnalises par des groupements hydrophobes et leurs applications notamment therapeutiques
US20050101605A1 (en) * 2003-11-07 2005-05-12 Ahmed Salah U. Oral liquid formulations of methotrexate
FR2862536B1 (fr) * 2003-11-21 2007-11-23 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques
US8529939B2 (en) * 2003-12-08 2013-09-10 Gel-Del Technologies, Inc. Mucoadhesive drug delivery devices and methods of making and using thereof
US20050143303A1 (en) * 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
US20060210614A1 (en) * 2003-12-26 2006-09-21 Nastech Pharmaceutical Company Inc. Method of treatment of a metabolic disease using intranasal administration of exendin peptide
US20080318837A1 (en) * 2003-12-26 2008-12-25 Nastech Pharmaceutical Company Inc. Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
US20060074025A1 (en) * 2003-12-26 2006-04-06 Nastech Pharmaceutical Company Inc. Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
TW200529890A (en) * 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations
EP1718258B1 (de) 2004-02-23 2009-03-25 Euro-Celtique S.A. Missbrauchsichere transdermale abgabevorrichtung für opioide, enthaltend opioidantagonist in form von mikrokügelchen
US20050208134A1 (en) * 2004-02-25 2005-09-22 Shlomo Magdassi Biocompatible polymeric beads and use thereof
US20050244495A1 (en) 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US20090215898A1 (en) * 2004-03-04 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US20050245614A1 (en) * 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US7947739B2 (en) 2004-03-04 2011-05-24 Ferring B.V. Tranexamic acid formulations
US8022106B2 (en) * 2004-03-04 2011-09-20 Ferring B.V. Tranexamic acid formulations
JPWO2005094789A1 (ja) * 2004-03-31 2008-02-14 Ａｓｐｉｏｎ株式会社 Ｓ／ｏ型製剤およびその製造方法
GB0408308D0 (en) 2004-04-14 2004-05-19 Vectura Ltd Pharmaceutical compositions
WO2005107714A2 (en) * 2004-05-05 2005-11-17 Alkermes Controlled Therapeutics, Inc. Method of forming microparticles that include a bisphosphonate and a polymer
MXPA06012992A (es) * 2004-05-12 2007-02-12 Baxter Int Microesferas que comprenden proteina y que muestran inyectabilidad en altas concentraciones de este agente.
JP2007537288A (ja) * 2004-05-12 2007-12-20 バクスター インターナショナル インコーポレイテッド オリゴヌクレオチド含有マイクロスフェア、１型糖尿病を処置する医薬の製造のための、その使用
DK2072040T3 (da) 2004-05-12 2013-07-29 Baxter Healthcare Sa Terapeutisk anvendelse af nukleinsyremikrokugler
US8728525B2 (en) * 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
WO2006009602A2 (en) 2004-06-16 2006-01-26 Tap Pharmaceutical Products, Inc. Multiple ppi dosage form
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
TW200613012A (en) * 2004-07-02 2006-05-01 Takeda Pharmaceuticals Co Sustained-release composition, process for producing the same and use of the same
EP2583717B1 (de) 2004-07-28 2019-02-20 Medtronic Ardian Luxembourg S.à.r.l. Verfahren und Vorrichtungen für die Nierennervenblockade
FR2873703B1 (fr) * 2004-07-30 2006-12-08 Flamel Technologies Sa Polyaminoacides branches, fonctionnalises par des groupements hydrophobes et leurs applications notamment therapeutiques
FR2873704B1 (fr) * 2004-07-30 2006-12-08 Flamel Technologies Sa Polyaminoacides fonctionnalises par des greffons hydrophobes portant une charge anionique et leurs applications notamment therapeutiques
US20060040894A1 (en) * 2004-08-13 2006-02-23 Angiotech International Ag Compositions and methods using hyaluronic acid
TW200613004A (en) * 2004-08-31 2006-05-01 Aspion Co Ltd External preparation of solid/oil type
US20070254314A1 (en) * 2004-09-16 2007-11-01 Geier Mark R Methods of treating autism and autism spectrum disorders
ATE536175T1 (de) * 2004-09-17 2011-12-15 Univ Massachusetts Zusammensetzungen und ihre verwendungen bei lysosomalen enzymstörungen
EP2156826A1 (de) * 2004-09-27 2010-02-24 Sigmoid Pharma Limited Mikrokapselformulierung mit zwei pharmazeutischen Wirkstoffen
US8313763B2 (en) * 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
EP1804751A2 (de) * 2004-10-04 2007-07-11 QLT USA, Inc. Okulare abgabe von polymer-abgabeformulierungen
ES2255426B1 (es) 2004-10-19 2007-08-16 Gp Pharm, S.A. Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
AU2005302453A1 (en) * 2004-10-29 2006-05-11 Medimmune, Llc Methods of preventing and treating RSV infections and related conditions
US7937143B2 (en) 2004-11-02 2011-05-03 Ardian, Inc. Methods and apparatus for inducing controlled renal neuromodulation
DK1824460T3 (en) * 2004-11-10 2015-01-19 Tolmar Therapeutics Inc Stabilized polymeric delivery system
US20080207109A1 (en) * 2005-01-06 2008-08-28 Oy Halton Group Ltd. Ventilation Register and Ventilation Systems
FR2881140B1 (fr) * 2005-01-27 2007-04-06 Flamel Technologies Sa Copolyhydroxyalkylglutamines fonctionnalises par des groupements hydrophobes et leurs applications notamment therapeutiques
CA2604225A1 (en) * 2005-04-27 2006-11-02 Baxter International Inc. Surface-modified microparticles and methods of forming and using the same
EP1726299A3 (de) * 2005-05-27 2007-04-18 StratoSphere Pharma AB Kerne und Mikrokapsel zur parenteralen Verabreichung sowie Verfahren zu deren Herstellung
US8017152B2 (en) 2005-05-27 2011-09-13 Stratosphere Pharma Ab Cores and microcapsules suitable for parenteral administration as well as process for their manufacture
JP5554496B2 (ja) * 2005-09-19 2014-07-23 ニューロナセント インコーポレイテッド 神経発生を刺激するための、およびニューロン変性を阻害するための方法および組成物
EP1948245B1 (de) * 2005-10-24 2011-10-05 University of Massachusetts Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
FR2892725B1 (fr) * 2005-10-31 2011-03-04 Flamel Tech Sa Acides polyglutamiques fonctionnalises par des derives de l'histidine et des groupements hydrophobes et leurs applications notamment therapeutiques
US8882747B2 (en) * 2005-11-09 2014-11-11 The Invention Science Fund I, Llc Substance delivery system
US20080286375A1 (en) * 2005-11-15 2008-11-20 Amorepacific Corporation Method for Preparing Sustained-Release Microparticles Comprising Sucrose Acetate Isobutyrate
US8546451B2 (en) * 2005-11-28 2013-10-01 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US8637706B2 (en) 2005-11-28 2014-01-28 Gtx, Inc. Nuclear receptor binding agents
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
WO2007067964A2 (en) * 2005-12-08 2007-06-14 Nastech Pharmaceutical Company Inc. Mucosal delivery of stabilized formulations of exendin
WO2007074604A1 (ja) * 2005-12-26 2007-07-05 Ltt Bio-Pharma Co., Ltd. 水溶性非ペプチド性低分子薬物含有ナノ粒子
CU23388B6 (es) 2006-01-31 2009-07-16 Ct Ingenieria Genetica Biotech Composición farmacéutica de microesferas para prevenir la amputación del pie diabético
KR100722607B1 (ko) 2006-05-11 2007-05-28 주식회사 펩트론 분산성 및 주사 투여능이 향상된 서방성 미립구의 제조방법
US9023400B2 (en) * 2006-05-24 2015-05-05 Flamel Technologies Prolonged-release multimicroparticulate oral pharmaceutical form
JP4720620B2 (ja) * 2006-05-30 2011-07-13 コニカミノルタビジネステクノロジーズ株式会社 カール補正装置及びこれを備えた画像形成装置
ES2575933T3 (es) 2006-05-31 2016-07-04 Baxter International Inc. Colágeno para su uso en la prevención de la formación de fibrosis epidural después de cirugía espinal
US20070281031A1 (en) * 2006-06-01 2007-12-06 Guohan Yang Microparticles and methods for production thereof
TWI436793B (zh) 2006-08-02 2014-05-11 Baxter Int 快速作用之乾密封膠及其使用和製造方法
CN105168146A (zh) * 2006-08-04 2015-12-23 巴克斯特国际公司 预防和/或逆转新发作自身免疫糖尿病的基于微球的组合物
US20080248122A1 (en) * 2006-10-06 2008-10-09 Baxter International Inc. Microencapsules Containing Surface-Modified Microparticles And Methods Of Forming And Using The Same
JP5196760B2 (ja) * 2006-10-27 2013-05-15 一般財団法人 九州医療資源財団 Ｗ／ｏ／ｗ型エマルジョン組成物
DK2442107T3 (da) 2006-11-01 2014-05-19 Ventana Med Syst Inc Haptener, haptenkonjugater, sammensætninger deraf og fremgangsmåde til deres fremstilling og anvendelse
US9289196B2 (en) 2006-12-12 2016-03-22 Cook Medical Technologies Llc Hemostatic substance with a coating
BRPI0720582B1 (pt) 2006-12-18 2021-08-24 Takeda Pharmaceutical Company Limited Composição de liberação prolongada, processo para a preparação da mesma, composição farmacêutica, agente profilático ou terapêutico, e, uso de uma substância fisiologicamente ativa
JP2010516625A (ja) 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
JP2010523554A (ja) 2007-04-04 2010-07-15 シグモイド・ファーマ・リミテッド タクロリムスの医薬組成物
EP2061587A1 (de) * 2007-04-26 2009-05-27 Sigmoid Pharma Limited Herstellung mehrerer minikapseln
CA2685593A1 (en) * 2007-05-01 2008-11-06 Sigmoid Pharma Limited Combination pharmaceutical compositions
FR2915748B1 (fr) 2007-05-03 2012-10-19 Flamel Tech Sa Acides polyglutamiques fonctionnalises par des groupes cationiques et des groupements hydrophobes et leurs applications, notamment therapeutiques
WO2008139804A1 (ja) 2007-05-14 2008-11-20 Ltt Bio-Pharma Co., Ltd. 徐放性の陰荷電基を持つ低分子薬物含有ナノ粒子
EP1997830A1 (de) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
US20080318994A1 (en) * 2007-06-21 2008-12-25 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Renal Impairment
PL2170340T3 (pl) 2007-06-21 2016-06-30 Neuronascent Inc Sposoby i kompozycje stymulacji neurogenezy i hamowania degeneracji neuronów z wykorzystaniem izotiazolopirymidonów
US20080318993A1 (en) * 2007-06-21 2008-12-25 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Hepatic Impairment
US10011763B2 (en) 2007-07-25 2018-07-03 Schlumberger Technology Corporation Methods to deliver fluids on a well site with variable solids concentration from solid slurries
US9040468B2 (en) 2007-07-25 2015-05-26 Schlumberger Technology Corporation Hydrolyzable particle compositions, treatment fluids and methods
WO2009028650A1 (ja) * 2007-08-29 2009-03-05 Yutoku Pharmaceutical Industries Co., Ltd. 乳化型外用剤およびその製造方法
KR20170097787A (ko) * 2007-10-12 2017-08-28 다케다 파마슈티칼스 유에스에이, 인코포레이티드 음식 섭취와 관계없이 위장 장애를 치료하는 방법
EP2222283A2 (de) * 2007-10-29 2010-09-01 University of Massachusetts Zur freisetzung von nukleinsäuren (sirna) mit hefe-zellwandproteinen verkapselte mehrlagige nanopatikel
CA2703103C (en) 2007-10-30 2017-05-09 Baxter Healthcare S.A. Use of a regenerative biofunctional collagen biomatrix for treating visceral or parietal defects
US20110027376A1 (en) * 2007-12-11 2011-02-03 Nanyang Technological University Hollow Multi-Layered Microspheres for Delivery of Hydrophilic Active Compounds
US11890371B2 (en) * 2007-12-26 2024-02-06 Petvivo Holdings, Inc. Biocompatible protein-based particles and methods thereof
WO2009086270A1 (en) * 2007-12-28 2009-07-09 Khashayar Kevin Neshat Controlled release local anesthetic for post dental surgery and method of use
US20090202642A1 (en) * 2008-02-08 2009-08-13 Xiao Huang Drug Delivery System Comprising Microparticles and Gelation System
EP2249817B8 (de) * 2008-02-18 2012-03-21 Csir Nanoteilchen-träger zur verabreichung von arzneimitteln und verfahren zu ihrer herstellung
RU2545810C2 (ru) 2008-02-29 2015-04-10 Ферросан Медикал Дивайсиз А/С Устройство для ускорения остановки кровотечения и/или заживления ран
KR100963435B1 (ko) * 2008-06-19 2010-06-17 한국과학기술연구원 서방형 약물전달 및 조직재생용 덮인 다공성 생분해성고분자 미립구의 제조 방법
WO2010009291A1 (en) * 2008-07-16 2010-01-21 Surmodics Pharmaceuticals, Inc. Process for preparing microparticles containing bioactive peptides
US8815818B2 (en) 2008-07-18 2014-08-26 Rxi Pharmaceuticals Corporation Phagocytic cell delivery of RNAI
US8034382B2 (en) * 2008-07-31 2011-10-11 The Board Of Trustees Of The University Of Arkansas Preparation method for biodegradable micro-particles containing drugs
US8323685B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
US8323615B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US20100047292A1 (en) * 2008-08-20 2010-02-25 Baxter International Inc. Methods of processing microparticles and compositions produced thereby
US8367427B2 (en) * 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
US20100062057A1 (en) * 2008-09-10 2010-03-11 Pronova BioPharma Norge AS. Formulation
AU2009293658A1 (en) 2008-09-22 2010-03-25 James Cardia Reduced size self-delivering RNAi compounds
WO2010047674A1 (en) 2008-10-20 2010-04-29 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Low molecular weight thyroid stimulating hormone receptor (tshr) agonists
US8653086B2 (en) 2008-10-21 2014-02-18 Oregon Health & Science University Naphthamides as anticancer agents
US10016534B2 (en) 2008-11-17 2018-07-10 Gel-Del Technologies, Inc. Protein biomaterial and biocoacervate vessel graft systems and methods of making and using thereof
US8652129B2 (en) 2008-12-31 2014-02-18 Medtronic Ardian Luxembourg S.A.R.L. Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
JP2012515790A (ja) * 2009-01-23 2012-07-12 サーモディクス ファーマシューティカルズ， インコーポレイテッド 微粒子製造のための連続二重エマルジョン工程
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
AU2010222648B2 (en) 2009-03-09 2016-07-07 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
EP2424488B1 (de) * 2009-04-27 2023-06-07 Premier Dental Products Company Mikroverkapselte zusammensetzungen und verfahren für gewebemineralisierung
US9814657B2 (en) 2009-04-27 2017-11-14 Premier Dental Products Company Buffered microencapsulated compositions and methods
US20100280117A1 (en) * 2009-04-30 2010-11-04 Xanodyne Pharmaceuticals, Inc. Menorrhagia Instrument and Method for the Treatment of Menstrual Bleeding Disorders
US9039783B2 (en) 2009-05-18 2015-05-26 Baxter International, Inc. Method for the improvement of mesh implant biocompatibility
DK2471518T3 (en) 2009-05-18 2017-12-04 Sigmoid Pharma Ltd COMPOSITION INCLUDING OIL DROPS
MX2011013795A (es) 2009-06-16 2012-04-30 Baxter Int Esponja hemostatica.
EP2464341B1 (de) 2009-08-12 2022-07-06 Sublimity Therapeutics Limited Immunmodulatorische zusammensetzungen mit einer polymermatrix und einer ölphase
GB0915480D0 (en) * 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
AU2010295646B2 (en) 2009-09-15 2016-02-11 Ellipses Pharma Limited Treatment of cancer
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
ES2363965B1 (es) 2009-11-20 2013-01-24 Gp Pharm S.A. Cápsulas de principios activos betabloqueantes y ésteres de ácidos grasos poliinsaturados.
ES2363964B1 (es) 2009-11-20 2012-08-22 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados.
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
US20110237540A1 (en) * 2009-11-23 2011-09-29 Crawford Thomas C Cyclodextrin-based polymers for therapeutic delivery
CA2784432C (en) 2009-12-16 2019-01-15 Baxter Healthcare S.A. Hemostatic sponge
MX2012006993A (es) 2009-12-23 2012-07-30 Defiante Farmaceutica Sa Composicion de combinacion util para el tratamiento de enfermedades cardiovasculares.
EP2515864A4 (de) * 2009-12-23 2013-09-11 Psivida Inc Vorrichtung mit verzögerter freisetzung
EP2353588B1 (de) * 2010-01-21 2015-04-15 Agricultural Technology Research Institute Präparat mit verzögerter Freisetzung von Faktor IX
US9365612B2 (en) 2010-01-29 2016-06-14 United States Of America As Represented By The Secretary, Department Of Health And Human Services Caspase inhibitors
US9205577B2 (en) * 2010-02-05 2015-12-08 Allergan, Inc. Porogen compositions, methods of making and uses
US9138309B2 (en) 2010-02-05 2015-09-22 Allergan, Inc. Porous materials, methods of making and uses
WO2011112709A1 (en) * 2010-03-09 2011-09-15 Elan Pharma International Limited Alcohol resistant enteric pharmaceutical compositions
DK2544532T3 (en) 2010-03-12 2017-06-06 Monsanto Technology Llc AGRICULTURAL GEL COMPOSITIONS
CN101816910B (zh) * 2010-03-25 2011-12-07 陕西师范大学 固载十六烷基三甲基磷钨酸季铵盐杂化微凝胶的制备方法
SA111320355B1 (ar) 2010-04-07 2015-01-08 Baxter Heathcare S A إسفنجة لايقاف النزف
CN102791705B (zh) 2010-04-08 2016-08-03 美国政府(由卫生和人类服务部的部长所代表) 用于tsh受体的反向激动剂和中性拮抗剂
US11202853B2 (en) * 2010-05-11 2021-12-21 Allergan, Inc. Porogen compositions, methods of making and uses
US20110300150A1 (en) 2010-05-18 2011-12-08 Scott Eliasof Compositions and methods for treatment of autoimmune and other disease
CN103037845B (zh) 2010-06-01 2015-11-25 巴克斯特国际公司 用于制备干燥、稳定的止血组合物的方法
CA2801116C (en) 2010-06-01 2019-02-12 Baxter International Inc. Process for making dry and stable hemostatic compositions
US9408945B2 (en) 2010-06-01 2016-08-09 Baxter International Inc. Process for making dry and stable hemostatic compositions
ES2385240B1 (es) 2010-07-26 2013-09-23 Gp-Pharm, S.A. Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata.
EP2603450B1 (de) 2010-08-14 2016-11-02 University of Massachusetts Wandpartikel aus hefezellen für rezeptorengerichtete nanopartikelfreisetzung
GB201016433D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Apparatus and method for making solid beads
GB201016436D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Method of making solid beads
US9132291B2 (en) 2010-10-05 2015-09-15 Dfb Technology, Ltd. Water-in-oil emulsion compositions containing gellan gum for topical delivery of active ingredients to the skin or mucosa
WO2012061153A1 (en) 2010-10-25 2012-05-10 Medtronic Ardian Luxembourg S.A.R.L. Devices, systems and methods for evaluation and feedback of neuromodulation treatment
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
US10821085B2 (en) 2010-12-07 2020-11-03 Kimberly-Clark Worldwide, Inc. Wipe coated with a botanical composition having antimicrobial properties
US8445032B2 (en) 2010-12-07 2013-05-21 Kimberly-Clark Worldwide, Inc. Melt-blended protein composition
US9149045B2 (en) 2010-12-07 2015-10-06 Kimberly-Clark Worldwide, Inc. Wipe coated with a botanical emulsion having antimicrobial properties
US9648874B2 (en) 2010-12-07 2017-05-16 Kimberly-Clark Worldwide, Inc. Natural, multiple use and re-use, user saturated wipes
US8524264B2 (en) 2010-12-07 2013-09-03 Kimberly-Clark Worldwide, Inc. Protein stabilized antimicrobial composition formed by melt processing
US9832993B2 (en) 2010-12-07 2017-12-05 Kimberly-Clark Worldwide, Inc. Melt processed antimicrobial composition
WO2012125486A1 (en) 2011-03-11 2012-09-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination chemotherapy for treating cancer
WO2012125787A1 (en) 2011-03-17 2012-09-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic METHODS FOR TREATING LEUKEMIA AND DISORDERS MEDIATED BY CBFβ AND RUNX1 PROTEINS
WO2013039792A1 (en) 2011-09-12 2013-03-21 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunogens based on an hiv-1 gp120 v1v2 epitope
WO2013049535A2 (en) 2011-09-30 2013-04-04 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Influenza vaccine
JP6195569B2 (ja) 2011-10-11 2017-09-13 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 止血組成物
MX346958B (es) 2011-10-11 2017-04-06 Baxter Int Composición hemostatica.
US9149528B2 (en) 2011-10-13 2015-10-06 Premier Dental Products Company Topical vitamin D oral supplement compositions
KR101975624B1 (ko) 2011-10-27 2019-05-07 백스터 인터내셔널 인코포레이티드 지혈 조성물
WO2013072767A1 (en) 2011-11-18 2013-05-23 Pronova Biopharma Norge As Compositions and preconcentrates comprising at least one salicylate and omega-3 fatty acid oil mixture
US8574628B2 (en) 2011-12-19 2013-11-05 Kimberly-Clark Worldwide, Inc. Natural, multiple release and re-use compositions
US9249103B2 (en) 2012-01-13 2016-02-02 Oregon Health & Science University Compounds, compositions and associated methods comprising 3-aryl quinolines
JP6241624B2 (ja) 2012-03-06 2017-12-06 フェロサン メディカル デバイシーズ エイ／エス 止血ペーストを収容する加圧容器
WO2013134548A2 (en) 2012-03-08 2013-09-12 Medtronic Ardian Luxembourg S.A.R.L. Ovarian neuromodulation and associated systems and methods
AU2013229776B2 (en) 2012-03-08 2016-12-15 Medtronic Af Luxembourg S.A.R.L. Biomarker sampling in the context of neuromodulation devices and associated systems
EP2827828A4 (de) 2012-03-21 2016-01-06 Univ Loma Linda Substanzen und verfahren zum ersatz von natürlichem zahnmaterial
EP2833881A1 (de) 2012-04-04 2015-02-11 Pronova BioPharma Norge AS Zusammensetzungen mit omega-3-fettsäuren und vitamin d für psoriase sowie verfahren und verwendungen davon
DK2833740T3 (da) 2012-04-04 2017-01-02 Pronova Biopharma Norge As Sammensætninger omfattende omega-3-fedtsyrer og D-vitamin til acne vulgaris og/eller eksem og fremgangsmåder og anvendelser deraf
ES2734567T3 (es) 2012-06-08 2019-12-10 Univ Pittsburgh Commonwealth Sys Higher Education Inhibidores de FBXO3
RU2636240C2 (ru) 2012-06-12 2017-11-21 Ферросан Медикал Дивайсиз А/С Сухая гемостатическая композиция
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
US9724542B2 (en) 2012-10-12 2017-08-08 Premier Dental Products Company Remineralizing and desensitizing compositions, treatments and methods of manufacture
US9877930B2 (en) 2012-10-12 2018-01-30 Premier Dental Products Company Topical ubiquinol oral supplement compositions with amorphous calcium phosphate
US20140110296A1 (en) 2012-10-19 2014-04-24 Medtronic Ardian Luxembourg S.A.R.L. Packaging for Catheter Treatment Devices and Associated Devices, Systems, and Methods
JP6272626B2 (ja) 2012-11-13 2018-01-31 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ カンナビノイド受容体媒介性化合物
US20140142522A1 (en) * 2012-11-16 2014-05-22 NU Technology, LLC Moist dressing with honeycomb pattern and drain channels
WO2014093702A1 (en) 2012-12-12 2014-06-19 The Usa, As Represented By The Secretary, Department Of Health And Human Services Hiv therapeutics and methods of making and using same
ES2748562T3 (es) 2013-02-28 2020-03-17 Basf As Una composición que comprende un compuesto lipídico, un triglicérido y un tensioactivo, y procedimientos de uso de la misma
KR101486132B1 (ko) 2013-03-20 2015-01-23 씨제이헬스케어 주식회사 졸-겔 변환 특성을 갖는 고분자를 이용한 미립구의 제조방법 및 이로부터 제조된 미립구
JP6230691B2 (ja) 2013-03-21 2017-11-15 ユープラシア ファーマシューティカルズ ユーエスエー エルエルシーＥｕｐｒａｘｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｕｓａ Ｌｌｃ 関節の炎症およびそれに関連する疼痛を治療するための注射用持続放出組成物およびその使用方法
KR101543507B1 (ko) 2013-05-15 2015-08-11 씨제이헬스케어 주식회사 연속 공정의 미립구의 제조 방법 및 이로부터 제조된 미립구
WO2014186398A1 (en) 2013-05-16 2014-11-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds for inhibiting drug-resistant strains of hiv-1 integrase
EP3010419B1 (de) 2013-06-21 2020-05-20 Ferrosan Medical Devices A/S Vakuumerweiterte trockenzusammensetzung und spritze zum zurückhalten davon
BR112016002342A8 (pt) 2013-08-06 2018-01-23 Dong Kook Pharm Co Ltd microesfera entecavir, método para preparação de uma microesfera entecavir, e, composição farmacêutica
CN103432093B (zh) * 2013-08-31 2015-03-25 西南大学 甲磺酸普立地诺骨架缓释片及其制备方法
JP6564380B2 (ja) 2013-09-20 2019-08-21 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 前立腺癌を治療するための化合物
WO2015054662A1 (en) 2013-10-10 2015-04-16 Eastern Virginia Medical School 4-((2-hydroxy-3-methoxybenzyl)amino) benzenesulfonamide derivatives as 12-lipoxygenase inhibitors
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
CA2931547A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
EP3079731B1 (de) 2013-12-11 2018-08-08 Ferrosan Medical Devices A/S Trockenzusammensetzung mit extrusionsverstärker
WO2015106003A1 (en) 2014-01-08 2015-07-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Ras pathways as markers of protection against hiv and methods to improve vaccine efficacy
US9980766B1 (en) 2014-03-28 2018-05-29 Medtronic Ardian Luxembourg S.A.R.L. Methods and systems for renal neuromodulation
US10194979B1 (en) 2014-03-28 2019-02-05 Medtronic Ardian Luxembourg S.A.R.L. Methods for catheter-based renal neuromodulation
US10194980B1 (en) 2014-03-28 2019-02-05 Medtronic Ardian Luxembourg S.A.R.L. Methods for catheter-based renal neuromodulation
DK3125871T3 (da) * 2014-03-31 2020-12-21 Pharmathen Sa Fremstilling af peptidladede plga-mikrosfærer med kontrolleret frigivelse-kendetegn
EP3140288B1 (de) 2014-05-09 2023-01-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Pyrazol-derivate und deren verwendung als mediatoren des cannabinoid-rezeptors
CA2959347C (en) 2014-08-25 2023-03-07 Salk Institute For Biological Studies Ulk1 inhibitors and methods using same
WO2016037154A1 (en) 2014-09-04 2016-03-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant hiv-1 envelope proteins and their use
AU2015333206B2 (en) 2014-10-13 2019-07-11 Ferrosan Medical Devices A/S. Dry composition for use in haemostasis and wound healing
US20160106804A1 (en) * 2014-10-15 2016-04-21 Yuhua Li Pharmaceutical composition with improved stability
WO2016064716A1 (en) 2014-10-20 2016-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination therapy of tshr antagonist and igfr inhibitor
PL3215127T3 (pl) 2014-11-07 2021-05-17 Sublimity Therapeutics Limited Kompozycje zawierające cyklosporynę
CN107206165B (zh) 2014-12-24 2020-10-23 弗罗桑医疗设备公司 用于保持并混合第一和第二物质的注射器
US10420834B2 (en) 2014-12-24 2019-09-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant metapneumovirus F proteins and their use
WO2016112036A1 (en) 2015-01-05 2016-07-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Myc g-quadruplex stabilizing small molecules and their use
CN107848940A (zh) 2015-02-20 2018-03-27 俄勒冈健康科学大学 Sobeirome衍生物
US10093613B2 (en) 2015-04-21 2018-10-09 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
AU2016250562B2 (en) 2015-04-21 2020-08-13 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10314797B2 (en) 2016-06-10 2019-06-11 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10806720B2 (en) 2015-04-21 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
BR112017022860A2 (pt) 2015-04-21 2018-07-17 Gtx Inc ligantes de decompostos receptores de andrógeno seletivos (sard) e métodos de utilização dos mesmos
US10865184B2 (en) 2015-04-21 2020-12-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10017471B2 (en) 2015-04-21 2018-07-10 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10654809B2 (en) 2016-06-10 2020-05-19 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US9834507B2 (en) 2015-04-21 2017-12-05 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10441570B2 (en) 2015-04-21 2019-10-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) Ligands and methods of use thereof
US10035763B2 (en) 2015-04-21 2018-07-31 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
EP3288550A1 (de) 2015-04-28 2018-03-07 Pronova BioPharma Norge AS Verwendung strukturell von verbesserten schwefelhaltigen fettsäuren zur vorbeugung und/oder behandlung von nichtalkoholischer steatohepatitis
US20180273485A1 (en) 2015-06-04 2018-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Cannabinoid receptor mediating compounds
WO2017005590A1 (en) 2015-07-03 2017-01-12 Ferrosan Medical Devices A/S Syringe for mixing two components and for retaining a vacuum in a storage condition
US10799580B2 (en) 2015-09-09 2020-10-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Expression vector delivery system and use thereof for inducing an immune response
MX2018005035A (es) 2015-10-27 2018-09-06 Eupraxia Pharmaceuticals Inc Formulaciones de liberacion sostenida de anestesicos locales.
EP3411022B1 (de) 2016-02-01 2021-09-15 Emory University Teilchen für die gezielte freisetzung und verwendung beim management von blutungen und blutgerinnung
EP3423448A1 (de) 2016-03-04 2019-01-09 The U.S.A. as represented by the Secretary, Department of Health and Human Services Cannabinoid-rezeptorvermittelnde verbindungen
HUE056357T2 (hu) 2016-05-18 2022-02-28 Univ Oregon Health & Science Szobetirom származékok
US11230523B2 (en) 2016-06-10 2022-01-25 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10806719B2 (en) 2016-06-10 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
EP3471828A1 (de) 2016-06-16 2019-04-24 Acies Bio d.o.o. Zusammensetzungen und verfahren zur behandlung von krankheiten, die durch eine unzureichende pantothenatkinaseaktivität gekennzeichnet sind
EP3554538A2 (de) 2016-12-16 2019-10-23 Institute for Research in Biomedicine Neuartige rekombinante rsv-f-präfusionsproteine und verwendungen davon
US9962342B1 (en) * 2017-03-14 2018-05-08 Sunny Pharmtech Inc. Pharmaceutical composition containing guaifenesin and application thereof
US11052046B2 (en) 2017-09-26 2021-07-06 Nanomi B.V. Method for preparing micro-particles by double emulsion technique
WO2019099595A1 (en) 2017-11-14 2019-05-23 The Schepens Eye Research Institute, Inc. NANO-EMULSION OF CBFβ-RUNX1 INHIBITOR FOR OCULAR DRUG DELIVERY
IL275002B2 (en) 2017-12-06 2024-04-01 Basf As Fatty acid antecedents for the treatment of nonalcoholic fatty liver disease
WO2019118803A1 (en) 2017-12-14 2019-06-20 The United States Of America, As Represented By The Secretary,Department Of Health And Human Services Chemical entities for lytic activation of kshv and therapeutic targeting of viral enzymes/proteins
CN110123634A (zh) 2018-02-09 2019-08-16 株式会社理光 颗粒的制造方法，颗粒的制造装置，以及颗粒
BR112020018832A2 (pt) 2018-03-29 2021-02-09 Elex Biotech, Inc. compostos para o tratamento de arritimias cardíacas e insuficiência cardíaca
AU2019266529A1 (en) 2018-05-09 2020-12-03 Ethicon Inc. Method for preparing a haemostatic composition
WO2019222556A1 (en) 2018-05-16 2019-11-21 Gtx, Inc. Selective androgen receptor degrader (sard) ligands and methods of use thereof
FR3082842A1 (fr) 2018-06-21 2019-12-27 Veru Inc. Polymorphe de cis-clomiphene (zuclomiphene) et procedes d'utilisation de celui-ci
WO2020068657A1 (en) 2018-09-25 2020-04-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 2'-halogenated-4'-thio-2'-deoxy-5-azacytidine analogs and use thereof
US11827596B2 (en) 2018-12-12 2023-11-28 Autobahn Therapeutics, Inc. Thyromimetics
WO2020180624A1 (en) 2019-03-01 2020-09-10 Autobahn Therapeutics, Inc. Novel thyromimetics
EP3937917B1 (de) 2019-03-11 2023-11-15 Oregon State University Analoga und derivate von cephalotaxin und verfahren zur herstellung und verwendung der verbindungen
CN115666621A (zh) 2020-01-13 2023-01-31 度勒科特公司 具有减少的杂质的持续释放药物递送系统及相关方法
US20230285576A1 (en) 2020-08-05 2023-09-14 Ellipses Pharma Ltd Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
EP4352054A1 (de) 2021-06-09 2024-04-17 The United States of America, as represented by The Secretary, Department of Health and Human Services Verbindungen zur bindung nichtkanonischer g-quadruplex-strukturen und verfahren zur herstellung und verwendung davon
WO2023056368A1 (en) 2021-09-30 2023-04-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cyclic peptides as non-hormonal male contraceptive agents and methods of use thereof
WO2023059867A1 (en) 2021-10-08 2023-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds for treating or preventing alzheimer's disease
WO2023146771A1 (en) 2022-01-25 2023-08-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Gingerenone a prodrugs as senotherapeutics and methods of use
WO2023172751A1 (en) 2022-03-10 2023-09-14 University Of Massachusetts Devices and methods of treating wounds
WO2023177568A1 (en) 2022-03-14 2023-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cannabinoid receptor modulating compounds

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB929402A (en) * 1958-12-22 1963-06-19 Upjohn Co Encapsulated emulsions and processes for their preparation
US3092553A (en) * 1959-01-30 1963-06-04 Jr Carl E Fisher Pharmaceutical preparations and method and apparatus for making same
GB1298194A (en) * 1968-11-20 1972-11-29 Agfa Gevaert Improved method for encapsulating aqueous or hydrophilic material, the capsules obtained therewith and their application
NL280825A (de) * 1962-07-11
BE744162A (fr) * 1969-01-16 1970-06-15 Fuji Photo Film Co Ltd Procede d'encapsulage
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
BE759520A (fr) * 1969-11-28 1971-04-30 Aspro Nicholas Ltd Compositions d'aspirine
FR2236483B1 (de) * 1973-07-12 1976-11-12 Choay Sa
US4272398A (en) * 1978-08-17 1981-06-09 The United States Of America As Represented By The Secretary Of Agriculture Microencapsulation process
US4234571A (en) * 1979-06-11 1980-11-18 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
US4622244A (en) * 1979-09-04 1986-11-11 The Washington University Process for preparation of microcapsules
US4273920A (en) * 1979-09-12 1981-06-16 Eli Lilly And Company Polymerization process and product
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4637905A (en) * 1982-03-04 1987-01-20 Batelle Development Corporation Process of preparing microcapsules of lactides or lactide copolymers with glycolides and/or ε-caprolactones
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4555399A (en) * 1983-11-18 1985-11-26 Key Pharmaceuticals, Inc. Aspirin tablet
ATE61935T1 (de) * 1985-02-07 1991-04-15 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
JP2551756B2 (ja) * 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
US4710384A (en) * 1986-07-28 1987-12-01 Avner Rotman Sustained release tablets made from microcapsules
US4971893A (en) * 1987-03-30 1990-11-20 E. I. Du Pont De Nemours And Company Element containing lower gloss protective covering and a pre-press color proof

Also Published As

Publication number Publication date
ES8605983A1 (es) 1986-04-01
HUT37037A (en) 1985-11-28
EP0145240A2 (de) 1985-06-19
US5061492A (en) 1991-10-29
US4917893A (en) 1990-04-17
US4711782A (en) 1987-12-08
HU193910B (en) 1987-12-28
HK3792A (en) 1992-01-17
BG60493B2 (bg) 1995-05-31
EP0145240A3 (en) 1985-07-03
US5631021A (en) 1997-05-20
JPH0157087B2 (de) 1989-12-04
PT79450B (en) 1986-12-11
ES537325A0 (es) 1986-04-01
US5476663A (en) 1995-12-19
US5631020A (en) 1997-05-20
SG103491G (en) 1992-01-17
CA1233414A (en) 1988-03-01
EP0145240B1 (de) 1989-04-19
JPS60100516A (ja) 1985-06-04
PT79450A (en) 1984-12-01
US4652441A (en) 1987-03-24
IE842830L (en) 1985-05-04
GR80818B (en) 1985-03-04
IE57721B1 (en) 1993-03-24

Similar Documents

Publication Publication Date Title
DE3477732D1 (en) Method for producing microcapsule
GB8411941D0 (en) Producing microcapsule
DE3473604D1 (en) Process for producing polyetherglycol
BG40814A3 (en) Method for preparing nucleozides
DE3480519D1 (en) Microcapsules and method for their production
HUT35696A (en) Process for producing grf-analoques
DE3461018D1 (en) Method of preparing microcapsules
DE3479040D1 (en) Method for producing l-carnitine
HUT36841A (en) Process for producing 2-fluoro-17-beta-estradiol
DE3471334D1 (en) Method for forming structures
BG49272A3 (en) Method for preparing alkylbensols
GB2151613B (en) Process for producing 4-alkoxyanilines
DE3364653D1 (en) Method for producing crystals
HUT37434A (en) Process for producing acylamino-mitosanes
DE3460771D1 (en) Process for producing arginyl-p-nitroanilide
GB2140420B (en) Process for producing 2-quinoxalinols
DE3572886D1 (en) Method for producing electret-containing devices
PH21011A (en) Method for producing l-glutamic acid
GB2144118B (en) Method for preparing 4-methylionone
GB2148281B (en) Process for producing aminobenzylamines
DE3475299D1 (en) Process for producing m-hydroxyacetophenone
HUT36465A (en) Process for producing 2-isopropyl-4-methyl-6-hydroxy-pyrimidine
GB2149790B (en) Process for producing aminobenzylamines
GB2115372B (en) Process for producing micro-capsules
HUT36765A (en) Catalytic process for producing grignard-connection

Legal Events

Date Code Title Description
8364 No opposition during term of opposition